Cargando…

BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells

OBJECTIVE: BI6727, an ATP-competitive PLK1 inhibitor, has been shown to cause cell death in multi-tumors. This study aimed to investigate the anti-tumor effect and potential molecular mechanism of BI6727 in human Burkitt lymphoma (BL) cell lines. METHODS: We assessed polo-like kinase 1 (PLK1) expres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Er, Pei, Renzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Pre-Clinical Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263168/ https://www.ncbi.nlm.nih.gov/pubmed/32468878 http://dx.doi.org/10.1177/0300060520926093

Ejemplares similares

BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1
por: Gohda, Jin, et al.
Publicado: (2018)

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
por: Lin, C-C, et al.
Publicado: (2014)

Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAF(V600E) Mutant Melanoma Cells
por: Cholewa, Brian D., et al.
Publicado: (2014)

Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines
por: WeiΔ, Lilly Magdalena, et al.
Publicado: (2017)

Burkitt‐like lymphoma with 11q aberration
por: Collins, Katrina, et al.
Publicado: (2019)

Chemotherapeutic Efficacy of Phosphodiesterase Inhibitors in Chagasic Cardiomyopathy
por: Wen, Jian-jun, et al.
Publicado: (2016)

Burkitt Lymphoma of the Duodenum
por: Matsueda, Katsunori, et al.
Publicado: (2017)

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment()
por: Liu, Xiaoqi
Publicado: (2015)

A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening
por: Abdelfatah, Sara, et al.
Publicado: (2018)

Polo-like kinase in trypanosomes: an odd member out of the Polo family
por: Kurasawa, Yasuhiro, et al.
Publicado: (2020)

Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain
por: Chen, Yunyu, et al.
Publicado: (2016)

Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2017)

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
por: Gjertsen, B T, et al.
Publicado: (2015)

Linear Regression QSAR Models for Polo-Like Kinase-1 Inhibitors
por: Duchowicz, Pablo R.
Publicado: (2018)

Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases
por: Hennenberg, Martin, et al.
Publicado: (2018)

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia
por: Gopalakrishnan, Bhavani, et al.
Publicado: (2018)

Putting a bit into the polo-box domain of polo-like kinase 1
por: Park, Jung-Eun, et al.
Publicado: (2015)

Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors
por: Jadhav, Mrunal, et al.
Publicado: (2021)

The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells
por: Dong, Jianwen, et al.
Publicado: (2018)

The balance of Polo-like kinase 1 in tumorigenesis
por: Lu, Lin-Yu, et al.
Publicado: (2009)

The CINs of Polo-Like Kinase 1 in Cancer
por: Cunningham, Chelsea E., et al.
Publicado: (2020)

Design and Synthesis of a Cell-Permeable, Drug-Like Small Molecule Inhibitor Targeting the Polo-Box Domain of Polo-Like Kinase 1
por: Srinivasrao, Ganipisetti, et al.
Publicado: (2014)

Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma
por: Gonzalez-Farre, Blanca, et al.
Publicado: (2019)

Computational Design of Targeted Inhibitors of Polo-Like Kinase 1 (Plk1)
por: Jani, Krupa S., et al.
Publicado: (2012)

Prostaglandin-like substances in Burkitt lymphoma tissue.
por: Ajayi, O. O., et al.
Publicado: (1977)

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate
por: Abdelfatah, Sara, et al.
Publicado: (2019)

Development of a Novel Cell-Permeable Protein–Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1
por: Huggins, David J., et al.
Publicado: (2019)

BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells
por: Lian, Guodong, et al.
Publicado: (2018)

Polo‑like kinase 1 selective inhibitor BI2536 (dihydropteridinone) disrupts centrosome homeostasis via ATM‑ERK cascade in adrenocortical carcinoma
por: Lin, Ruei-Ci, et al.
Publicado: (2023)

Toll-like receptor 2/4 inhibitors can reduce preterm birth in mice
por: Jing, Xu, et al.
Publicado: (2020)

Proof-of-concept of a laser mounted endoscope for touch-less navigated procedures
por: Kral, Florian, et al.
Publicado: (2013)

In vivo optical signatures of neuronal death in a mouse model of Alzheimer's disease
por: Lin, Alexander J, et al.
Publicado: (2014)

Aerobic training and L-arginine supplement attenuates myocardial infarction-induced kidney and liver injury in rats via reduced oxidative stress
por: Ranjbar, Kamal, et al.
Publicado: (2018)

Biochemical and histological changes in the heart of post-partum rats exposed to Natron
por: Saidu, Yusuf, et al.
Publicado: (2018)

Follistatin-Like 1 Regulates Hypertrophy in Heart Failure With Preserved Ejection Fraction
por: Tanaka, Komei, et al.
Publicado: (2016)

SBE13, a newly identified inhibitor of inactive polo-like kinase 1
por: Keppner, Sarah, et al.
Publicado: (2010)

A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis
por: Imakura, Takeshi, et al.
Publicado: (2023)

Polo-like kinase-1 in DNA damage response
por: Hyun, Sun-Yi, et al.
Publicado: (2014)

Polo-like kinase 1 as target for cancer therapy
por: Weiß, Lily, et al.
Publicado: (2012)

Playing POLO-like kinase in NRAS mutant melanoma
por: Chen, Hsin-Yi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_25t6132m6io2suoju00kucg91u